Mumbai: Diagnostics company Thyrocare Technologies Ltd. on Thursday announced the launch of its GLP-1 Health Check, a set of comprehensive testing packages designed to help monitor individuals using GLP-1–based medicines for weight loss and type 2 diabetes …

In this briefing: Relaxo Footwears Ltd. - Soft Quarter, Steady Recovery Expected; Maintain HOLD VIP Industries Ltd - Weak Quarter, Near-Term Challenges Drag Profitability China’s Bank-Centric Funding: An Under-Reported Risk Allied Blenders and Distillers: The Transformation Story from Mass Market to Luxury Spirits Thyrocare Technologies Limited: Positioned for the GLP-1 Diagnostics 1. Relaxo Footwears Ltd. - Soft Quarter, Steady Recovery Expected; Maintain HOLD Soft Quarter: Relaxo reported a sharp 7.5% YoY revenue decline, due to demand softness in the mass market segment and delayed purchases ahead of the implementation of GST 2.0. Meanwhile, general trade remained subdued during the quarter, as distributors and channel partners focused on clearing legacy inventory ahead of the transition. Management expects this softness to be temporary, with normalisation anticipated over the next few quarters as the channel replenishes stocks. R Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

In this briefing: China’s Bank-Centric Funding: An Under-Reported Risk Allied Blenders and Distillers: The Transformation Story from Mass Market to Luxury Spirits Thyrocare Technologies Limited: Positioned for the GLP-1 Diagnostics OpenAI. Is The Narrative Slowly Disintegrating ? The Beat Ideas: Dharmaj Crop Guard - From Capex Drag to Operating Leverage Propellant 1. China’s Bank-Centric Funding: An Under-Reported Risk China’s bank-centric funding model is an under-reported risk that appears to be lost amidst the current rally in Chinese stocks While it powered China’s investment boom previously, this model now misallocates capital, warehouses property losses on bank balance sheets, blunts PBoC easing, prolongs deflation risks and echoes Japan-style balance-sheet stagnation Without credible bank clean-up and a shift toward bond, equity and REIT funding, China’s rally risks remaining tactical rather than structural. The current rally does not signal a multi-year bull-run 2. Allied Blenders and Distillers: The Transformation Story from Mass Market to Luxury Spirits Allied Blenders & Distillers is transitioning from a mass-market to a premium-led portfolio , with strong brands like Officer’s Choice, ICONiQ White, and Sterling Reserve driving growth.

In this briefing: Allied Blenders and Distillers: The Transformation Story from Mass Market to Luxury Spirits Thyrocare Technologies Limited: Positioned for the GLP-1 Diagnostics OpenAI. Is The Narrative Slowly Disintegrating ? The Beat Ideas: Dharmaj Crop Guard - From Capex Drag to Operating Leverage Propellant Primer: SG Mart (SGMART IN) - Nov 2025 1. Allied Blenders and Distillers: The Transformation Story from Mass Market to Luxury Spirits Allied Blenders & Distillers is transitioning from a mass-market to a premium-led portfolio , with strong brands like Officer’s Choice, ICONiQ White, and Sterling Reserve driving growth. This transformation aligns ABD with India's growing premium alcohol market, driven by shifting consumer preferences , premiumisation trends , and increased disposable income , positioning the company for future growth. ABD’s strategic focus on premiumisation , combined with robust capex plans, positions it to capitalize on evolving market dynamics, though regulatory risks and competition remain key challenges. 2.

In this briefing: Thyrocare Technologies Limited: Positioned for the GLP-1 Diagnostics OpenAI. Is The Narrative Slowly Disintegrating ? The Beat Ideas: Dharmaj Crop Guard - From Capex Drag to Operating Leverage Propellant Primer: SG Mart (SGMART IN) - Nov 2025 APAC Healthcare Weekly (November 16) – Leads Bio, Henlius Bio, Otsuka, ABL Bio, Boryung, Eubiologics 1. Thyrocare Technologies Limited: Positioned for the GLP-1 Diagnostics The generic availability of GLP-1 drugs from 2026 presents a structural, high-volume, and repetitive diagnostics opportunity that perfectly fits Thyrocare's low-cost, centralized B2B model. Thyrocare Technologies (THYROCAR IN) reported robust Q2 FY'26 consolidated revenue growth of 22% YoY, coupled with a normalized EBITDA margin expansion to 34.8%. Strong execution and quality improvements position Thyrocare to capture this multi-year GLP-1-driven volume surge. 2. OpenAI. Is The Narrative Slowly Disintegrating ? Fresh on the heels of his podcast meltdown, Mr.

Nifty ended higher after a late rebound driven by financials, pharma, and FMCG, supported by sentiment linked to the NDA’s Bihar victory. Technical indicators suggest strength above key support levels. Analysts recommend GRSE and Thyrocare based on strong breakouts, robust volume patterns, and sustained momentum across major moving averages

The company declared an interim dividend of ₹7 per share and announced a 2:1 bonus issue

Analysts see Nifty facing resistance near 25,300, with key support at 25,000.